Concepedia

Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status

Josef Rüschoff, Michael Friedrich, Iris Nagelmeier, Matthias Kirchner, Lena Andresen, Karin Salomon, Bryce P. Portier, Simone Treiger Sredni, Hans‐Ulrich Schildhaus, Bharat Jasani,

Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2022 · 78 citations · 21 references

Open access

References

21

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi, William Jacot, Toshinari Yamashita et al. · New England Journal of Medicine · 2022 · 2.3K citations · Full text

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi, Cristina Saura, Toshinari Yamashita et al. · New England Journal of Medicine · 2019 · 1.9K citations · Full text

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Antonio C. Wolff, M. Elizabeth Hammond, Kimberly H. Allison et al. · Archives of Pathology & Laboratory Medicine · 2018 · 1.4K citations · Full text

Amplification of a Novel v- <i>erb</i> B-Related Gene in a Human Mammary Carcinoma

C. Richter King, Matthias H. Kraus, Stuart A. Aaronson · Science · 1985 · 1.1K citations

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

Shanu Modi, Haeseong Park, Rashmi K. Murthy et al. · Journal of Clinical Oncology · 2020 · 786 citations · Full text